Osmol Therapeutics Inc
Osmol Therapeutics Inc, located in New Haven, CT, is dedicated to developing innovative treatment options for cancer patients at risk of chemotherapy-induced peripheral neuropathy (CIPN) and cognitive impairment (CICI). Their lead drug, OSM0205, aims to prevent neuronal damage associated with these debilitating side effects, allowing for optimal chemotherapy dosing and improved patient outcomes.
With a focus on both physical and cognitive well-being, Osmol's groundbreaking approach targets the critical interactions that initiate neuronal damage, addressing a significant unmet need in cancer care. Their commitment to enhancing patient quality of life reflects a transformative vision for the future of cancer treatment.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.